HallenbeckJ. Pathophysiologies of dyspnea explained: Why might opioids relieve dyspnea and not hasten death?J Palliat Med, 2012; 15,8:848–853.
2.
ViolaR, KiteleyC, LloydNS, MackayJA, WilsonJ, WongRKS. The management of dyspnea in cancer patients: A systematic review. Support Care Cancer, 2008; 16:329–337.
3.
PinnaMAC, VargasRM, MoraloMJR, CorreasMAS, BlancoGP. Dyspnea: A bad prognosis symptom at the end of life. Am J Hosp Palliat Care, 2009; 26,2:89–97.
4.
Ben-AharonI, Gafter-GviliA, PaulM, LeiboviciL, StemmerSM. Interventions for alleviating cancer-related dyspnea: A systematic review. J Clin Oncol, 2008; 26,14:2396–2404.
5.
CurrowDC, PlummerJ, FrithP, AbernethyAP. Can we predict which patients with refractory dyspnea will respond to opioids?J Palliat Med, 2007; 10,5:1031–1036.
6.
AbernethyAP, CurrowDC, FrithP, FazekasBS, BuiA, BuiM, BuiC. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ, 2003; 327:523–528.
7.
A systematic review of the use of opioids in the management of dyspnea. JenningsA-L, DaviesAN, HigginsJPT, GibbsJSR, BroadleyKE. Thorax, 2002; 57,11:939–944.
